EN DE
Watch Sionna Therapeutics, Inc. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Sionna Therapeutics, Inc. (SION) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Sionna Therapeutics, Inc. stock $3.26, price $2.97, upside +9.8%, quality 39 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US8294011080

ST Sionna Therapeutics, Inc. logo Thin data Nov 14, 2026

Sionna Therapeutics, Inc.

SION · US

The stock is already about fairly priced and weak company.

Follow free in the weekly email
Fair value $3.26 · Fairly valued 
Mixed vs. peers (2/5) 
Insiders sold $40.5M (6M) 
Quality 39/100 
Negative free cash flow 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Sionna Therapeutics, Inc. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$51.04 $2.97 Fair Value $3.26 Feb 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

21‑month range $2.97 – $51.04 · fair‑value band $2.45 – $4.08 · the $2.97 price screens below the $3.26 fair value. As of Nov 14, 2026.

Follow Sionna Therapeutics in your weekly email

Every Wednesday you see whether Sionna Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Show moreShow less

The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Stock analysis

Sionna Therapeutics, Inc. (SION) currently trades at $2.97, while our estimate is $3.26, so the stock looks roughly fairly valued today (gap 8.9%).

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.45 (bear) to $4.08 (bull), the price of $2.97 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Sionna Therapeutics, Inc. reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$75.3M in FY2025.

Key figures

Market cap $138M Micro · EPS (TTM) $-2.43 · Return on equity −39.0% · Return on assets (EBIT) −52.4% (4-year average) · Free cash flow −$66.7M · Net cash $49.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 94% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at 10%, SION screens cheaper than that median.

Fair Value

Bear $2.45 Fair Value $3.26 Bull $4.08
Price $2.97 · Upside +9.8%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 90
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $40.5M and none bought.

  • SaleRA CAPITAL MANAGEMENT, L.P.Director, 10% owner3,448,811 shares at $6.33$21.8MSep 17, 2026
  • SaleOrbiMed Capital GP VIII LLCDirector4× since Dec 17, 2025: 152,102 shares, avg. $44.73$6.8MJul 7, 202610b5-1 plan
  • SalePeter A. ThompsonDirector10× since Nov 24, 2025: 1,235,000 shares, avg. $45.08$55.7MJul 7, 202610b5-1 plan
  • SaleJennifer FitzpatrickChief Legal Officer3× since Dec 5, 2025: 30,750 shares, avg. $39.33$1.2MJul 6, 202610b5-1 plan
  • SaleORBIMED ADVISORS LLCDirector6× since Nov 24, 2025: 1,082,898 shares, avg. $45.13$48.9MJun 30, 202610b5-1 plan
  • SaleJon Winkelried10% owner250,000 shares at $40.00$10.0MJan 22, 2026
  • SalePeter KolchinskyDirector, 10% owner30,316 shares at $39.61$1.2MNov 21, 2025

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 19, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SION, get fair value alerts →

Compare Sionna Therapeutics, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside +9.8% · Top 25%
Profitability
Return on assets −23.1% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.45× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)46 · sector 2
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $923.34 $1,275.02 +38% vs SION
Vertex Pharmaceuticals Incorporated VRTX $520.66 $587.62 +13% vs SION
Samsung Biologics Co 207940 ₩1,375,000 ₩1,512,500 +10% vs SION
argenx SE ARGX $942.04 $908.40 −4% vs SION
CSL Limited CSL A$197.29 A$188.80 −4% vs SION
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs SION
Moderna, Inc MRNA $199.33 $122.98 −38% vs SION
Revolution Medicines, Inc RVMD $159.43 $83.12 −48% vs SION
Celltrion, Inc 068270 ₩215,000 ₩74,574 −65% vs SION
Royalty Pharma plc RPRX $67.72 $19.01 −72% vs SION

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sionna Therapeutics, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sionna Therapeutics, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/SION

Frequently asked questions

Is Sionna Therapeutics, Inc. (SION) overvalued or undervalued?
As of Nov 14, 2026, our estimate of fair value is $3.26 versus a price of $2.97, about +10% upside (fairly valued).
What is the fair value of SION?
Our estimate for Sionna Therapeutics, Inc. is $3.26 (as of Nov 14, 2026), built from audited fundamentals. The current price: $2.97.
What is the quality score of SION?
Sionna Therapeutics, Inc. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sionna Therapeutics, Inc. (SION)?
We do not set a price target; the yardstick is our estimate of $3.26 (as of Nov 14, 2026). Cautious scenario $2.45, optimistic scenario $4.08. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Sionna Therapeutics, Inc. stock forecast for 2026?
Our estimate puts fair value at $3.26, about +10% upside versus a price of $2.97 (fairly valued). Cautious scenario $2.45, optimistic scenario $4.08. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Sionna Therapeutics, Inc. (SION)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sionna Therapeutics, Inc. it is $3.26 per share (as of Nov 14, 2026), against a price of $2.97.
Is Sionna Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of Nov 14, 2026, SION trades below its calculated fair value: price $2.97, fair value $3.26, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SION?
No. The price is what the market pays today ($2.97); the fair value is what the company's own numbers justify ($3.26). For Sionna Therapeutics, Inc. the two are $0.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sionna Therapeutics, Inc. worth?
The market values Sionna Therapeutics, Inc. at about $138M (market capitalisation, as of Nov 14, 2026). Per share that is $2.97; our models calculate a fair value of $3.26 per share.
What do the bullish and bearish scenarios say about SION?
Our models span a range for Sionna Therapeutics, Inc.: cautious scenario $2.45, base $3.26, optimistic $4.08 per share (as of Nov 14, 2026, price $2.97). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sionna Therapeutics, Inc. (SION)?
Balance-sheet figures for Sionna Therapeutics, Inc. (as of Nov 14, 2026): return on equity −39.0%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is SION from its 52-week high?
Sionna Therapeutics, Inc. trades at $2.97, about 94% below its 52-week high of $51.04 and at the low of $2.97 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of $3.26 is for.
Which stocks are comparable to Sionna Therapeutics, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sionna Therapeutics, Inc. stock attractive at the current price?
The data as of Nov 14, 2026: price $2.97, calculated fair value $3.26 (+10%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Sionna Therapeutics, Inc. currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sionna Therapeutics, Inc. (SION)?
The closing price on Nov 19, 2026 was $2.97. Our estimate is $3.26, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sionna Therapeutics, Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sionna Therapeutics, Inc.

How large is the market capitalisation of Sionna Therapeutics, Inc. (SION)?
The market capitalisation of Sionna Therapeutics, Inc. is $138M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sionna Therapeutics, Inc. (SION)?
Earnings per share at Sionna Therapeutics, Inc. are $-2.43. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sionna Therapeutics, Inc. (SION)?
The return on equity (ROE) of Sionna Therapeutics, Inc. is −39.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sionna Therapeutics, Inc. (SION)?
On an EBIT basis the return on assets of Sionna Therapeutics, Inc. is −52.4% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Sionna Therapeutics, Inc. (SION) generate?
The free cash flow of Sionna Therapeutics, Inc. is −$66.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sionna Therapeutics, Inc. (SION) hold?
Sionna Therapeutics, Inc. holds more cash than debt, $49.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sionna Therapeutics, Inc. in the live analysis

One click puts Sionna Therapeutics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.